Literature DB >> 21178954

Experimental metastasis and CTL adoptive transfer immunotherapy mouse model.

Mary Zimmerman1, Xiaolin Hu, Kebin Liu.   

Abstract

Experimental metastasis mouse model is a simple and yet physiologically relevant metastasis model. The tumor cells are injected intravenously (i.v) into mouse tail veins and colonize in the lungs, thereby, resembling the last steps of tumor cell spontaneous metastasis: survival in the circulation, extravasation and colonization in the distal organs. From a therapeutic point of view, the experimental metastasis model is the simplest and ideal model since the target of therapies is often the end point of metastasis: established metastatic tumor in the distal organ. In this model, tumor cells are injected i.v into mouse tail veins and allowed to colonize and grow in the lungs. Tumor-specific CTLs are then injected i.v into the metastases-bearing mouse. The number and size of the lung metastases can be controlled by the number of tumor cells to be injected and the time of tumor growth. Therefore, various stages of metastasis, from minimal metastasis to extensive metastasis, can be modeled. Lung metastases are analyzed by inflation with ink, thus allowing easier visual observation and quantification.

Entities:  

Mesh:

Year:  2010        PMID: 21178954      PMCID: PMC3159593          DOI: 10.3791/2077

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  17 in total

1.  CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.

Authors:  Kebin Liu; Sheila A Caldwell; Kristy M Greeneltch; Dafeng Yang; Scott I Abrams
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

Review 2.  Tumor escape mechanism governed by myeloid-derived suppressor cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

3.  Accurate identification of experimental pulmonary metastases.

Authors:  H Wexler
Journal:  J Natl Cancer Inst       Date:  1966-04       Impact factor: 13.506

4.  Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.

Authors:  M H Ryan; J A Bristol; E McDuffie; S I Abrams
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells.

Authors:  Dafeng Yang; Muthusamy Thangaraju; Kristy Greeneltch; Darren D Browning; Patricia V Schoenlein; Tomohiko Tamura; Keiko Ozato; Vadivel Ganapathy; Scott I Abrams; Kebin Liu
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

7.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

8.  IFN regulatory factor 8 mediates apoptosis in nonhemopoietic tumor cells via regulation of Fas expression.

Authors:  Dafeng Yang; Muthusamy Thangaraju; Darren D Browning; Zheng Dong; Borys Korchin; Dina C Lev; Vadivel Ganapathy; Kebin Liu
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

9.  Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression.

Authors:  Dafeng Yang; Trina J Stewart; Kimberly K Smith; David Georgi; Scott I Abrams; Kebin Liu
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

10.  Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.

Authors:  Dafeng Yang; Najam Ud Din; Darren D Browning; Scott I Abrams; Kebin Liu
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

View more
  7 in total

1.  A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.

Authors:  Katherine A Murphy; Britnie R James; Andrew Wilber; Thomas S Griffith
Journal:  J Vis Exp       Date:  2017-04-12       Impact factor: 1.355

2.  An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis.

Authors:  Amy V Paschall; Kebin Liu
Journal:  J Vis Exp       Date:  2016-08-14       Impact factor: 1.355

3.  Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis.

Authors:  Huabin Zhu; John D Klement; Chunwan Lu; Priscilla S Redd; Dafeng Yang; Alyssa D Smith; Dakota B Poschel; Juan Zou; Ding Liu; Peng George Wang; David Ostrov; Nicolas Coant; Yusuf A Hannun; Aaron H Colby; Mark W Grinstaff; Kebin Liu
Journal:  J Immunol       Date:  2021-02-05       Impact factor: 5.422

4.  FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577.

Authors:  Wei-Tao Zhang; Ji-Jun Zhang; Quan Shao; Ying-Kai Wang; Jie-Peng Jia; Bo Qian; Xiao-Wen Tian; Wen-Ji Yan
Journal:  Oncol Rep       Date:  2021-11-25       Impact factor: 3.906

5.  MicroRNA-1246 Mediates Drug Resistance and Metastasis in Breast Cancer by Targeting NFE2L3.

Authors:  Yue-Chu Dai; Yin Pan; Ming-Ming Quan; Qi Chen; Yue Pan; Yan-Yun Ruan; Jian-Guo Sun
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

6.  G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.

Authors:  Chunwan Lu; Dafeng Yang; John D Klement; Yolonda L Colson; Nicholas H Oberlies; Cedric J Pearce; Aaron H Colby; Mark W Grinstaff; Han-Fei Ding; Huidong Shi; Kebin Liu
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

7.  LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.

Authors:  Tina Chang Albershardt; David James Campbell; Andrea Jean Parsons; Megan Merrill Slough; Jan Ter Meulen; Peter Berglund
Journal:  Mol Ther Oncolytics       Date:  2016-03-30       Impact factor: 7.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.